← Leaderboards
Margo Cohen
Exocell, Inc.
$4,912,764
Attributed
$4,912,764
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–07$2M$1.5M$1M$500K$0
'05
'06
'07
Funding mix
By agency
NIH$4,912,764 · 7
By mechanism
R44$4,608,506 · 4
R43$304,258 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Glycation”
- Ann Marie Schmidt · Beckman Research Institute/City Of Hope$22,223,935
- Ravi Kalhan · Northwestern University At Chicago$15,411,918
- Jose A Halperin · Harvard University (Medical School)$15,359,581
- Ravichandran Ramasamy · Columbia University Health Sciences$13,563,319
- Shi Du Yan · Columbia University Health Sciences$13,214,809
- Jose A Luchsinger · Columbia University Health Sciences$11,146,487
Research focus
GlycationDrug Screening /EvaluationDrug Design /Synthesis /ProductionClinical ResearchDiabetic NephropathyLaboratory RatHuman SubjectDrug Adverse EffectDiabetes MellitusDiabetes Mellitus TherapyToxicologyGlomerulosclerosisTransforming Growth FactorsHypoglycemic AgentsClinical Trial Phase IiClinical Trial Phase IPharmacokineticsBioengineering /Biomedical EngineeringHuman Therapy EvaluationHigh Performance Liquid ChromatographyHemoglobin AsHuman TissueBlood TestsBlood Glucose
Grant awards (12)
LDL Modification in Diabetic Complications$1,129,672
R44 · FY2007 · DK · contact PI
LDL Modification in Diabetic Complications$641,272
R44 · FY2006 · DK · contact PI
Reducing Renal TGF-B in Diabetic Glomerulosclerosis$264,000
R44 · FY2005 · DK
LDL Modification and Diabetic Renal Dysfunction$104,298
R43 · FY2005 · DK
Reducing Renal TGF-B in Diabetic Glomerulosclerosis$600,752
R44 · FY2004 · DK
Point-of-Care Measurement of Glycated Hemoglobin$287,693
R44 · FY2004 · DK
Reducing Renal TGF-B in Diabetic Glomerulosclerosis$250,000
R44 · FY2004 · DK
Reducing Renal TGF-B in Diabetic Glomerulosclerosis$636,114
R44 · FY2003 · DK
Point-of-Care Measurement of Glycated Hemoglobin$429,904
R44 · FY2003 · DK
Point-of-Care Measurement of Glycated Hemoglobin$100,000
R43 · FY2002 · DK
Reducing Renal TGF-B in Diabetic Glomerulosclerosis$99,960
R43 · FY2002 · DK
NOVEL AGENTS TO PREVENT KIDNEY DISEASE IN DIABETES$369,099
R44 · FY2000 · DK